Bagsværd, Denmark, 22 April 2015 - At Novo Nordisk's Annual General Meeting on 19 March 2015, it was decided to reduce the company's B share capital from DKK 422,512,800 to DKK 412,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.
Further information
| Media: | ||
| Anne Margrethe Hauge | +45 3079 3450 | amhg@novonordisk.com |
| Investors: | ||
| Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com (mailto:krop@novonordisk.com) |
| Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com (mailto:dabo@novonordisk.com) |
| Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com (mailto:mrz@novonordisk.com) |
| Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com (mailto:fdni@novonordisk.com) |
Company announcement No 27 / 2015
Company announcement no 27 / 2015 (http://hugin.info/2013/R/1913419/683321.pdf)
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
HUG#1913419
